67. L. A. Frohman and T. R. Downs, Methods Enzymol. 124, 371 (1986 From ES Cells to Germ Line Chimera Thus, the ratio will be dependent on the thresholds set by the selection conditions.
Nonselectable Genes
The advantages of hprt-its presence as a single copy in male cells and the ability to use direct selection as a way of isolating homologous recombinants-are not the case for most genes of interest. It is also possible to use the cis-acting regulatory sequences of the target gene in order to enrich for successful recombination events.
In this case, the targeting vector is designed in such a way that expression of the selectable marker, neo, depends on homologous integration to supply a missing promoter or enhancer, as described by Jasin and Berg (15) The HSV-tk gene is lost during the process of homologous recombination because it is located distal to the region of homology between the vector and the target. Only cells in which random integration of the targeting vector has occurred will be able to retain the HSV-tk gene. This is predicted from the observation that most random insertions of exogenous, linearized DNA into the genome occur via their ends (18) . Therefore, by using G418 to select for cells that contain a functional neor gene and by using gancyclovir to select against cells that contain a functional HSV-tk gene, we can enrich for cells in which the targeting event has occurred.
We have tested the above PNS approach by using it to disrupt the mouse hprt, int-2, hox 1.2, and hox 1.3 genes (17, 19) and observed as much as a 2000-fold enrichment for targeted disruptions.
Targeting into Genes Not Expressed in ES Cells
An ideal strategy for disrupting a gene not expressed in ES cells
has not yet emerged. Preliminary attempts in which the PNS procedure was used to mutate one such gene, the proto-oncogene int-1, suggests that the targeting frequency is much lower than that Immunology appears to be a particularly fertile field for genetic analysis by gene targeting. It is by far the best characterized cellular system in mammals, and extensive molecular analysis has identified many of the genetic components responsible for immunological diversity. Further, since the immune system is dispensable, analysis of many of the null phenotypes should be simplified. Approximately 3500 different human genetic diseases are known.
As the genes responsible for these diseases are identified and cloned, disruption of the corresponding genes in the mouse should provide 1292 useful models for these human diseases. Such models will facilitate analysis of the pathology of the disease and provide a system for the exploration of new therapeutic protocols including gene therapy.
A new arena for biotechnology is the application of transgenesis to the improvement of domestic animals and plants, as well as for the production of rare products such as pharmaceuticals within domestic animals (as discussed in this issue). These efforts will certainly be complemented and augmented by the use of gene targeting to modify the host genome. Transgenesis and gene targeting are often directed towards different ends, the former being used to gain new functions, the latter being used to augment or to generate loss of existing functions. As regulatory loops become better defined, it should become possible to alter such loops by gene targeting, thereby reducing the production of undesired products (such as fat content in meat) or increasing the production of desired products (such as pharmaceuticals in milk). The power of gene targeting resides in the ability of the experimenter to precisely choose both the gene to be modified and the specific change to be introduced.
